TAGline 2004
2004 issues (December, October, September, August, July, June, May, April, March, February, January) of TAGline
Report from the 3rd International TB/HIV Community Workshop
By Bob Huff December 2004 Introduction The 3rd International Community TB/HIV Workshop was held in Paris from October 26-29, 2004. Participants were nominated by organizations and networks from all regions. From 229 applicants the Advisory Committee — Beverley Figaji (Namibia),…
ICAAC Roundup, 2004
The Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) is the annual meeting of the American Society for Microbiology. In 2004, it happened in Washington DC from 30 Oct to 2 Nov. Some new drugs were presented along with data…
Brand-name FDCs and PEPFAR, 2004
September 2004 By Rob Camp In January 2003, W announced PEPFAR, The President's Emergency Plan For AIDS Relief, pledging 15 billion dollars of funding over 5 years, to provide testing and treatment in 15 countries affected by HIV/AIDS. Critique of…
TAG Testimony to the FDA Vaccines and Related Biological Products Advisory Committee
Regarding the U.S. Military/NIAID-Sponsored RV144 ALVAC/AIDSVAX "Prime-Boost" Vaccine Trial in Thailand By Richard Jefferys September 28, 2004 On September 23, 2004, the US Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee held a hearing to discuss the…
Epzicom Brand Abacavir-Lamivudine QD
The Difference Between Drugs and New Drugs By Rob Camp August 2004 FDA announced approvals in early August of two fixed-dose combination (FDC) antiretroviral drug products for use with other antiretroviral agents for the treatment of HIV-1 infection. FDCs are…
Two Out of Three Ain’t Bad
In early August, FDA announced approvals of two fixed-dose combination (FDC) antiretroviral drug products for use with other antiretroviral agents in the treatment of HIV-1 infection: GlaxoSmithKline's Epzicom® (abacavir/lamivudine) and Gilead Sciences, Inc.'s Truvada® (tenofovir disoproxil/emtricitabine).
Hepatitis C Virus (HCV) and HIV/HCV Coinfection: A Critical Review of Research and Treatment
July 2004 By Tracy Swan & Daniel Raymond INTRODUCTION TAG’s Hepatitis C and HIV/HCV Coinfection Report is a comprehensive review of basic and clinical science accompanied by recommendations for research and policy. It was written for people living with hepatitis…
NIH Hearing on Norvir 400% Price Increase, 2004
By Rob Camp Edited by Jen Curry AIDS Treatment Activists Coalition (ATAC) On Tuesday, May 25, 2004, the National Institutes of Health (NIH) hosted a public meeting to seek comment from invited individuals, organizations, and other stakeholders on the use…
Pharmacokinetic (PK) Issues and Drug-Drug Interaction Studies, 2004
Debra B Birnkrant, MD Center for Drug Evaluation and Research Office of New Drugs Division of Anti-Viral Products (HFD-530) CRPII/Rm. N414 Food and Drug Administration 5630 Fishers Lane, Rm 1061 Rockville, MD 20852 Fax: 301.827.2523 Dear Dr Birnkrant, I am…